AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A vaccine containing cold adapted, live, attenuated influenza virus and trivalent, subunit inactivated influenza virus improves the immune response of elderly patients to influenza vaccination, according to researchers in Russia.
L. Stepanova and colleagues at the St. Petersburg Pasteur Institute divided 47 young adults (19-35 years old) and 43 elderly adults (58-91 years old) into four groups. The subjects in each group received either a cold-adapted, live, attenuated influenza vaccine (LIV), a trivalent, subunit inactivated influenza vaccine (IIV), a combination of LIV and IIV (LIV/IIV), or a placebo. Investigators collected blood samples at the beginning of the study and 4 weeks after vaccination.
Measurements to assess immune response included hemagglutination inhibition (HAI) antibody response to homologous strains, and the enzyme-linked immunosorbent assays (ELISA) IgA, IgG and IgG-subclass responses to recombinant HA proteins representing influenza A and B strains from 90 to 91, and purified virus from an A/Sydney/05/97-like strain.
Vaccination with IIV alone or with LIV/IIV increased HAI titers to protective levels (>40) in both young and elderly adults. The young adults, but not the elderly, who received LIV had a influenza-specific IgG subclass response consisting of IgG1 and IgG4. IgG subclass response in the elderly subjects after IIV consisted of IgG1, but IgG1 and IgG3 in the young subjects (The humoral response to live and ...